摘要【目的】探讨岩黄连注射液辅助FOLFOXIRI化疗对晚期结直肠癌患者免疫功能及临床效果的影响。【方法】回顾性分析2017年3月至2020年3月本院收治的102例晚期结直肠癌患者的临床资料,根据治疗方案的不同将其分为观察组(予以岩黄连注射液辅助FOLFOXIRI化疗)和对照组(予以FOLFOXIRI化疗),每组各51例。比较两组患者临床疗效、生存质量改善情况,并比较两组治疗前后血清血管新生指标[转化生长因子-β1(TGF-β1)、低氧诱导因子-1α(HIF-1α)、血管内皮生长因子(VEGF)]、免疫功能指标(CD3+、CD4+、CD4+/CD8+)、肿瘤标志物[癌胚抗原(CEA)、糖类抗原199(CA199)、糖类抗原125(CA125)]。【结果】治疗后,观察组总有效率为54.90%,显著高于对照组的35.29%,差异具有统计学意义( P <0.05); 观察组患者生存质量改善率为66.67%,显著高于对照组的41.18%,差异具有统计学意义( P <0.05);两组患者血清TGF-β1、HIF-1α、VEGF、CEA、CA199、CA125水平低于治疗前,且观察组低于对照组,差异具有统计学意义( P <0.05);观察组患者血清CD3+、CD4+、CD4+/CD8+水平与治疗前相比,差异无统计学意义( P >0.05);对照组上述指标低于治疗前,观察组高于对照组,差异具有统计学意义( P <0.05)。【结论】应用岩黄连注射液辅助FOLFOXIRI化疗治疗晚期结直肠癌患者可抑制血管新生,降低肿瘤标志物表达,减轻免疫功能损伤,改善患者生存质量,值得临床推广应用。
Abstract：【Objective】To explore the effects of Yanhuanglian injection assisted FOLFOXIRI chemotherapy on the immune and clinical treatment in patients with advanced colorectal cancer. 【Methods】A retrospectively randomized control study was conducted in 102 patients with advanced colorectal cancer in our hospital from March 2017 to March 2020. They were divided into the observation group ( n =51) and the control group ( n =51) according to a random number table. Patients in the control group received FOLFOXIRI chemotherapy, and patients in the observation group received Yanhuanglian injection assisted FOLFOXIRI chemotherapy. Both groups were treated for 4 chemotherapy cycles. The efficacy and quality of life improvement rate, serum angiogenesis indicators [transforming growth factor-β1 (TGF-β1), hypoxia inducible factor-1α (HIF-1α), vascular endothelial growth factor (VEGF)], immune function index (CD3+, CD4+, CD4+/CD8+), tumor markers [carcinoembryonic antigen (CEA), carbohydrate antigen 199 (CA199), carbohydrate antigen 125 (CA125)] levels before and after treatment were compared between the two groups. 【Results】The total effective rate and the improvement rate of quality of life after 4 cycles of chemotherapy in the observation group were 54.90% and 66.67%, respectively, which were higher than 35.29% and 41.18% in the control group ( P <0.05). Serum levels of TGF-β1, HIF-1α, VEGF, CEA, CA199, CA125, and miR-217 in the two groups after treatment for 4 cycles of chemotherapy were lower than those before treatment. And the levels in the observation group was lower than those in the control group. After treatment, serum levels of CD3+, CD4+, CD4+/CD8+ in the observation group were not statistically different from those before treatment ( P >0.05). The above indicators in the control group were lower than before treatment; and the difference was statistically significant ( P <0.05). Serum levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group after 4 cycles of chemotherapy ( P <0.05). 【Conclusion】The application of Yanhuanglian injection assisted FOLFOXIRI chemotherapy in the treatment of patients with advanced colorectal cancer can inhibit angiogenesis, reduce the expression of tumor markers, reduce immune function damage and improve efficacy and quality of life.
樊雷, 宋香妮. 岩黄连注射液辅助FOLFOXIRI化疗治疗晚期结直肠癌患者临床疗效观察[J]. 医学临床研究, 2021, 38(3): 424-427.
FAN Lei, SONG Xiang-ni. Application of Yanhuanglian Injection Assisted FOLFOXIRI Chemotherapy in Treatment of Patients with Advanced Colorectal Cancer. JOURNAL OF CLINICAL RESEARCH, 2021, 38(3): 424-427.
2021, Vol. 38 
